 Iterum Therapeutics plc NASDAQ: ITRM has agreed with the FDA under the special protocol assessment SPA process on the design, endpoints, and statistical analysis of a Phase 3 trial for oral sulopenem etzadroxil-probenecid for uncomplicated urinary tract infections. The pivotal. 